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Abstract
Objective: The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to
evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of
children and adults and in patients with acromegaly.
Participants: GRS invited 34 international experts including clinicians, basic scientists, a
regulatory scientist and physicians from the pharmaceutical industry.
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Evidence: Current literature was reviewed and expert opinion was utilized to establish
the state of the art and identify current gaps and unmet needs.
Consensus process: Following plenary presentations, breakout groups discussed
questions framed by the planning committee. The attendees re-convened after each
breakout session to share the group reports. A writing team compiled the breakout
session reports into a document that was subsequently discussed and revised by
participants. This was edited further and circulated for final review after the meeting.
Participants from pharmaceutical companies were not part of the writing process.
Conclusions: The clinical endpoint in paediatric GH treatment is adult height with height
velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible
clinical endpoint of GH treatment in adult GH-deficient patients (GHDA) and in patients
with acromegaly. The pragmatic clinical endpoints in GHDA include normalization
of body composition and quality of life, whereas symptom relief and reversal of
comorbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker,
even though it correlates weakly with clinical endpoints in GH treatment, whereas in
acromegaly, normalization of IGF-I may be related to improvement in mortality. There
is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in
relation to GH treatment and in patients with acromegaly.
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Introduction
Biological markers (biomarkers) play an essential role
in the clinical care of patients, drug development and
regulatory approval. Furthermore, biomarkers are
linked to surrogate endpoints and clinical endpoints
(1, 2, 3, 4). The requirement for rigorous procedures
utilizing biomarkers in drug development is evident and
recognized (2, 5). The obvious biomarkers of growth
hormone (GH) action in children and adults are serum
levels of GH itself and of insulin-like growth factor-I
(IGF-I). Both are used diagnostically; IGF-I is used to
monitor the effects of GH replacement in GH deficiency
(GHD), and both GH and IGF-I are used in the diagnosis
and management of acromegaly. While serum IGF-I level
is used as a surrogate endpoint in trials involving GH
treatment and medical treatment of acromegaly, neither
GH nor IGF-I has been subject to a structured evaluation
as biomarkers, nor do we have a comprehensive
definition of clinical endpoints for the treatment of
GH-related disorders. Therefore, there is a need to define
clinically relevant endpoints and identify and evaluate
current and novel surrogate endpoints and biomarkers
of therapies targeting GH.
The Growth Hormone Research Society (GRS)
convened a Workshop in Aarhus, Denmark, on November
15–18, 2017 to review the current state of the field and
address key issues regarding the definition of clinical
endpoints for GH therapy and treatment of acromegaly,
to critically evaluate current surrogate endpoints for
http://www.endocrineconnections.org
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GH therapy and treatment of acromegaly and to discuss
novel and potential biomarkers of GH action in children
and adults.

Methods
The structure of this Workshop was adapted from prior
Workshops organized by GRS (6, 7, 8). Thirty-four
invited international leaders from twelve countries
across five continents participated. These included
paediatric and adult endocrinologists, basic scientists, a
European medicines regulator and physicians from the
pharmaceutical industry. A review of the current status
of clinical endpoints and biomarkers was written prior to
the meeting. A planning committee of the GRS comprised
academic adult and paediatric endocrinologists who
determined the agenda, selected speakers to summarize
key relevant topics and formulated the questions for
discussion.
Following presentations that summarized the
literature, three breakout groups addressed each topic in
more detail by discussing the list of questions formulated
by the planning committee and subsequently agreed upon
by all participants. All attendees re-convened after each of
the breakout sessions to share reports from the groups.
At the end of days 1 and 2, a writing team compiled
the breakout group reports into a final document that
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License.
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was discussed and reviewed in its entirety and revised
by participants on the concluding day. When there was
no clear agreement by most participants, consensus
was reached by voting. This draft document was edited
further for formatting and references, and subsequently
circulated to the academic attendees for final review after
the meeting. Meeting participants from pharmaceutical
companies, who participated in the Workshop, were not
part of the writing team and were not present during
text revision on the final day, but they were shown the
manuscript before submission to identify factual errors.
This report is a concise chronicle of the Workshop and is
not intended to be an exhaustive review of the literature
on this topic. It was written utilizing: (1) the content from
the speaker presentations and the current literature in the
field, (2) the combined comments of the breakout groups
to the questions and (3) the collective remarks of the
entire group during report-back sessions.

Definitions
The following terms and definitions, which derive from an
NIH expert working group (1) were used in the Workshop:
Clinical endpoint: A characteristic or variable that
reflects how a patient feels, functions or survives.
Biomarker: A characteristic that is objectively measured
and evaluated as an indicator of normal biological
processes, pathogenic processes or pharmacological
responses to a therapeutic intervention.
Surrogate endpoint: A biomarker that is intended to
substitute for a clinical endpoint. A surrogate endpoint
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is expected to predict benefit (or harm or lack of
benefit or harm) based on epidemiologic, therapeutic,
pathophysiologic or other scientific evidence.
A major emphasis was made on measures of treatment
efficacy and safety.

Clinical and surrogate endpoints during
GH treatment
Paediatric GH therapy
Adult height is the ultimate clinical endpoint of GH
therapy in children (9), although it is recognized that
normalization of height during childhood, independent
of eventual height, is an additional goal. A uniform
definition of adult height in the context of GH therapy
in children is not available, but a pragmatic definition
used in several trials have been a height gain <2 cm over
the last 12 months. In clinical practice and in clinical
trials, change in height velocity (cm/year) or change
in height standard deviation score (SDS) are used as
surrogate endpoints of efficacy and to monitor adherence
to therapy in individual children with GHD (Table 1). In
children being treated with GH for non-GHD conditions,
the change in height velocity or height SDS is used
as surrogate endpoints. In patients with Prader–Willi
syndrome, although auxological measures are important,
measures of the metabolic actions of GH are also valuable,
including change in body mass index (BMI) and body
composition (10). This also applies to other conditions
such as children born small for gestational age. Growth
response during the first year of GH treatment for short

Table 1 Current clinical endpoints, surrogate endpoints and biomarkers in GH therapy and acromegaly.
Patients and treatments

Clinical efficacy endpoints

Surrogate endpoints

Biochemical biomarker

Paediatric GH treatment
 GH deficiency

Adult height

Change in height SDS/growth
velocity
Peak bone mass, DXA Z score, LBM,
and FM
Change in height SDS/growth
velocity
Neuro-cognition
Muscle tone
Anthropometry, DXA Z score, LBM
and FM
Questionnaires
IGF-I, GH
Symptom scores

IGF-I

 GH deficiency in the transition period Body composition
 CRI, Noonan syndrome, SHOX, Turner Adult height
syndrome, SGA, SRS, ISS
 Prader–Willi syndrome
Body composition
Adult height
Adult GH treatment
Body composition
Quality of life
Acromegaly treatment

Serum IGF-I and GH
reduction
Symptom relief

IGF-I
IGF-I
IGF-I
IGF-I
IGF-I

CRI, chronic renal insufficiency; DXA, dual X-ray absorptiometry; FM, fat mass; IGF-I, insulin-like growth factor I; ISS, idiopathic short stature; LBM, lean
body mass; SDS, standard deviation score; SGA, small for gestational age; SHOX, short stature homeobox deficiency; SRS, Silver–Russell syndrome.
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stature is correlated with growth rates in subsequent years
and adult height. Prediction models using auxology, bone
age and other variables have been advocated as tools for
individual patient management (10, 11, 12). Measurement
of body proportions can be helpful in certain subgroup
of patients, such as cancer survivors receiving spinal
radiation. Bone age and decrease in growth velocity
can be used as biomarkers for epiphyseal maturation to
determine the time at which GH treatment should cease.

Transition from childhood to adult GH
replacement therapy
At the time when a patient reaches adult height, GHD
is either reconfirmed by retesting or recognised as a lifelong condition based on the underlying pathology. Since
growth can no longer be used as a biomarker, the clinical
focus in patients during the transition turns to adult
endpoints, such as peak bone mass and body composition
including fat mass and lean body mass (13).

Adult GH replacement
Adult patients are only treated when there is an
established diagnosis of GHD with the goal of replacing
the insufficient hormone. Adult GHD is recognized as a
syndrome with various and multifactorial comorbidities
affecting different organ systems (14). Therefore, the
impact of GH therapy cannot be directly correlated
with a single clinical endpoint. Unlike in paediatric GH
therapy, where measurement of growth is central to all
GH-treated patients, the goals of adult GH replacement
therapy take into consideration age, functional status and
comorbidities.
Clinical endpoints for GH replacement in adults with
GHD include body composition and quality of life (QoL).
Measurement of body composition may include waist
circumference, dual-energy X-ray absorptiometry (DXA)
scan for bone mineral density and content (BMD/BMC),
and where available, fat distribution such as truncal fat
and lean body mass (Table 1). The routine consultation
should include patient reported outcomes such as mood,
motivation, energy levels, physical mobility, activities of
daily living and employment. Formal questionnaires are
used in some health systems to determine the eligibility
for treatment and to monitor response to therapy (15).
A reduction in excess mortality in adult GHD would
be an ideal clinical endpoint, but such data are unlikely
to be forthcoming. The information available suggests
there is an increased mortality in adult patients with
http://www.endocrineconnections.org
https://doi.org/10.1530/EC-18-0047
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hypopituitarism including GHD due to cardiovascular
(CV) disease (16). Therefore, biomarkers for CV risk,
including blood pressure, visceral fat, lipids and highsensitive C-reactive protein (hsCRP), are commonly
measured.
Safety is monitored by asking about GH side effects,
including oedema, carpal tunnel syndrome and joint
pains and via measurement of haemoglobin A1C (HbA1C)
levels.

Biochemical biomarkers during GH treatment
IGF-I
Serum IGF-I is a biomarker of GH status, often being low in
GHD and high in GH excess. It is not subject to the diurnal
variation or pulsatility that is characteristic of endogenous
GH secretion. GH has direct, IGF-I-independent actions
as well as indirect effects mediated through hepatic and
local tissue IGF-I production. Serum IGF-I, which mainly
reflects liver-derived IGF-I, is suppressed during catabolic
conditions and has significant within-individual and
inter-assay variability (7, 17, 18). Despite these limitations,
measurement of serum IGF-I levels is currently used as a
biomarker for GH action (Table 1).

Use of serum IGF-I in paediatric GH treatment
Measurement of serum IGF-I during GH therapy in
children is used as a biomarker for adherence. Its
relationship to growth rate and final height is influenced
by other variables including bone age, birth length and
nutritional status, and it therefore has a limited role as
a marker of efficacy. This is particularly true for subsets
of non-GHD patients, who may have some degree of
associated GH and IGF-I insensitivity (19). Failure to raise
serum IGF-I concentrations during GH treatment may be
an early indication of GH insensitivity and could warrant
further evaluation and alternative treatments (20).
The increase in IGF-I with GH treatment is dose
dependent and dosing can be adjusted with a goal of
attaining an IGF-I within the normal range. However, as
noted earlier, serum IGF-I has proved disappointing as a
direct correlate to clinical outcome, but it is currently the
best option available. This highlights the need for new
biomarkers to predict the efficacy and safety of therapy in
individual patients.
IGF-I is also used as a long-term safety marker during
GH treatment. This practice is based on an extrapolation
from epidemiologic data in healthy adult populations, and
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License.
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meta-analyses and life course data in patients with
acromegaly that have shown an increase in morbidity and
mortality of subjects having upper-normal or consistently
elevated IGF-I levels (6). Nevertheless, modestly and
transiently elevated serum IGF-I concentrations in
GH-treated paediatric patients have not been linked
to adverse effects. There are no accepted guidelines for
IGF-I levels during GH treatment in GHD children, but
where possible, IGF-I should be maintained within the
normal range, although modest elevations above +2 s.d.
may be acceptable under certain circumstances. During
the treatment of non-GHD states, in order to achieve an
acceptable growth response, IGF-I may transiently be above
the normal range; however, the safety implications are
unknown.
Use of serum IGF-I in transition and adult GHD
During GH replacement, the GH dose in adults is titrated
to target IGF-I levels within the normal range. Serum IGF-I
levels do not correlate well with clinical endpoints, but
may help guiding dose titration. Despite the limitations
noted earlier, it is used as a biomarker for safety. GH
dose during the transition period is typically in-between
paediatric and adult doses, with adjustment primarily
based on serum IGF-I, just as in adult patients (13).
Insulin-like growth factor-binding protein 3 (IGFBP3), acid-labile subunit (ALS) and bioactive IGF-I
IGF-binding protein 3 (IGFBP-3) is the major carrier protein
for IGF-I in serum. There are limited data indicating that
IGFBP-3 predicts GH responsiveness or safety. However,
epidemiologic data suggest that high IGFBP-3 levels may
reduce the IGF-I-associated risk of certain cancers (21).
Therefore, additional studies measuring IGF-I, IGFBP-3
and their molar ratio during GH therapy as safety markers
may be useful. Bioactive IGF-I as measured by the kinasereceptor activation (KIRA) assay is a useful research tool and
accurately reflects changes in GH-responsive proteins (22).
However, this assay is labour-intensive and costly and at the
current time cannot be utilized in large clinical studies or
clinical practice. The ALS is a GH-dependent protein, but its
usefulness in clinical practice has not been established (23).

Biomarkers in the context of long-acting
growth hormone (LAGH) products
Neither daily GH administration nor LAGH recapitulate
the natural pattern of GH secretion. Unlike daily
GH, steady state IGF-I levels do not occur with LAGH
http://www.endocrineconnections.org
https://doi.org/10.1530/EC-18-0047
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products. Each of these novel products has a unique
pharmacodynamic (PD) profile, which means that they
cannot be considered as a homogenous group. Modelling
approaches based on PD measurement can be used to
indicate the optimal time for serum IGF-I measurement
for dose titration purposes (24). The relationship between
IGF-I and IGFBP-3 may also be different among the
various LAGH products (25). Since some of these agents
are GH analogues as opposed to authentic GH, they may
potentially exert other biological effects that could affect
safety and efficacy. This suggests there may be a need to
develop biomarkers that are specific for a given LAGH
product. Given the differences among these products,
specific pharmacovigilance programmes may be essential
for each LAGH product (8).

Clinical endpoints and biomarkers
in acromegaly
Acromegaly is diagnosed by a combination of clinical
signs and symptoms, pituitary MRI, and increased serum
IGF-I and GH levels. Therapeutic options include surgery,
medical therapy and radiotherapy. There remain a number
of clinical controversies, which might be addressed by
improved biomarkers.
Key clinical endpoints in acromegaly are amelioration
of the signs, symptoms and comorbidities associated
with tumour mass effect and excess GH secretion, with
the goal of normalization of life expectancy. Composite
scoring/grading systems for acromegaly disease activity,
which combine clinical, histopathology, tumour
characteristics and biochemical parameters, have been
developed. However, they have not yet been adapted
and validated for individual patient care (26, 27). A
disease-related QoL questionnaire as well as a symptomscoring instrument have been developed and validated,
and they may serve as independent markers for patientrelated outcomes (28, 29).
Anthropometric measures such as changes in finger
thickness measured by ring size, lean body mass and fat
mass have been assessed using DXA and CT in clinical
trials, but these methods have not been applied uniformly
in clinical care. This indicates a need for validated tools
adapted for patient management.
Serum IGF-I and GH levels are established biomarkers
of disease activity in acromegaly and elevated levels
have been associated with excess mortality. IGF-I is the
most commonly measured biomarker for determining
the success of treatment (Table 1). GH can be valuable in
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
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assessing the effect of pituitary surgery and is an index
of completion of tumour removal. Clinical practice varies
regarding the method used to evaluate GH; random
measurements, oral glucose suppression of GH and ‘day
curves’ with timed measurements across the day have all
been used (30).
It can be difficult to determine whether treated
patients with discordant IGF-I and GH levels are
optimally controlled. There are a number of reasons
for this discrepancy, such as oral oestrogen treatment,
nutritional status, history of pituitary radiotherapy, assay
variability and inadequate reference ranges. In addition,
there are therapy-specific changes that can lead to this
discrepancy. For example, during somatostatin analogue
treatment, there is a reduction in serum IGF-I that is not
associated with a proportional reduction of GH (31).
Measurement of GH is not helpful during treatment with
GH receptor antagonists (32). Consideration of these
factors should be taken into account before making
therapeutic decisions.
Measurement of serum IGFBP-3 or ALS does not
provide additional value beyond serum IGF-I in the
routine management of patients with acromegaly.
Treatment should be monitored according to the
treatment-specific side effects. Monitoring of glucose
metabolism and CV risk factors is standard of care for
patients with acromegaly (33). Potent therapies for
acromegaly may result in overtreatment, as manifested as
subnormal levels of serum IGF-I.

Novel biomarkers – an unmet need
GH and IGF-I have been used as biomarkers for several
decades, and they have been essential to the management
of GH-treated patients and patients with acromegaly (17,
34). Improvements in assay sensitivity and specificity
and standardisation over the subsequent years have been
helpful, but markers more closely linked to efficacy and
safety endpoints are still needed (35).
Paediatric indications
In paediatrics, there is currently an unmet need for
better predictors of GH treatment efficacy in relation
to linear growth response, metabolic benefit and safety.
There is a need for biomarkers that reflect therapeutic
response in specific tissues such as the growth plate and
skeleton in a variety of disorders associated with short
stature. (36).
http://www.endocrineconnections.org
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Adult GH replacement
Serum IGF-I primarily reflects GH action in the liver
(37), but its relationship to clinically meaningful efficacy
endpoints such as measures of body composition is
limited in individual patients (38). Other GH-responsive
biomarkers can be measured, such as bone turnover
markers, but the long-term value of their measurement
in clinical practice is unknown. There is a major need for
biomarkers that reflect the diverse effects of GH therapy
on carbohydrate, protein and lipid metabolism as well as
QoL in a dose-dependent manner.

Acromegaly
The ideal biochemical biomarker of efficacy should
accurately reflect disease activity and be independent of
treatment modality. As with adult GHD, there is a need
for biomarkers that reflect improvement of metabolic
status during therapy. There is also a need for a biomarker
to predict optimal response to therapy, especially in
circumstances when GH and IGF-I are discordant.

Potential candidates
A number of GH-responsive markers including matrix
metalloproteinases 2 and 9, vascular endothelial growth
factor, isoforms of apolipoprotein A-1 and haptoglobin and
afamin have been identified (39, 40, 41). Their usefulness
as biomarkers should be established in future studies. GH
doping detection strategies have highlighted proteins such
as procollagen Type III N-peptide and other bone markers
in serum that may have utility in acromegaly management
in the future (42, 43). A pharmacogenomic study has
identified genetic biomarkers of responsiveness to GH
treatment of children with GHD or Turner syndrome, which
seems a promising future tool (44). In addition, circulating
levels of a degradation fragment of type X collagen, which
is a by-product of endochondral ossification, may provide a
tool to monitor growth in paediatric patients (45).

Conclusion
Adult height remains the clinical endpoint of GH
treatment in paediatric patients, and height velocity
during the first and second year after treatment initiation
is useful surrogate endpoints. In adult GHD patients,
a reduction in truncal fat mass is typically the main
clinical efficacy endpoint for regulatory purposes, but
This work is licensed under a Creative Commons
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improvement in QoL and physical fitness are also used
in clinical practice. Lowering of elevated IGF-I levels in
combination with symptom relief are efficacy endpoints
used both for regulatory approval of novel drugs for
acromegaly treatment and in clinical practice. Serum IGF-I
is above all the most widely used biochemical biomarker
during GH treatment as well as in acromegaly (Table 1);
nonetheless, serum IGF-I correlates only weakly with
clinical endpoints of efficacy.
There is an unmet need for novel biomarkers within the
field of GH treatment and acromegaly. Systems medicine
approaches using genomics, epigenomics, metabolomics
and proteomics may facilitate selection of patients for
therapy and improve prediction of clinical endpoints.
Therefore, such approaches deserve further study, and the
collection of suitable samples for biobanking should be
considered in relevant clinical trials. The identification
of novel biomarkers for action of GH requires access
to samples from prospective controlled interventional
trials. At present, numerous large-scale studies are being
undertaken to examine the efficacy of LAGH preparations
and new treatments for acromegaly, which provide the ideal
opportunity to prospectively identify such novel markers.
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The effects of treatment and the individual responsiveness to growth
hormone (GH) replacement therapy in 665 GH-deficient adults.
Journal of Clinical Endocrinology and Metabolism 1999 84 3929–3935.
(https://doi.org/10.1210/jcem.84.11.6088)
39 Randeva HS, Lewandowski KC, Komorowski J, Murray RD,
O’Callaghan CJ, Hillhouse EW, Stepien H & Shalet SM. Growth
hormone replacement decreases plasma levels of matrix
metalloproteinases (2 and 9) and vascular endothelial growth factor
in growth hormone–deficient individuals. Circulation 2004 109
2405–2410. (https://doi.org/10.1161/01.CIR.0000129763.51060.77)
40 Cruz-Topete D, Jorgensen JOL, Christensen B, SackmannSala L, Krusenstjerna-Hafstrøm T, Jara A, Okada S & Kopchick JJ.
Identification of new biomarkers of low-dose GH replacement
therapy in GH-deficient patients. Journal of Clinical Endocrinology and
Metabolism 2011 96 2089–2097. (https://doi.org/10.1210/jc.20110197)

Biomarkers of GH action

7:3

R134

41 Cruz-Topete D, Christensen B, Sackmann-Sala L, Okada S,
Jorgensen JOL & Kopchick JJ. Serum proteome changes in
acromegalic patients following transsphenoidal surgery: novel
biomarkers of disease activity. European Journal of Endocrinology 2011
164 157–167. (https://doi.org/10.1530/EJE-10-0754)
42 Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosén T, Dall R,
Boroujerdi MA, Bassett EE, Healy ML, Pentecost C, et al. Growth
hormone (GH) effects on bone and collagen turnover in healthy adults
and its potential as a marker of GH abuse in sports: a double blind,
placebo-controlled study. Journal of Clinical Endocrinology and Metabolism
2000 85 1505–1512. (https://doi.org/10.1210/jcem.85.4.6551)
43 Nguyen TV, Nelson AE, Howe CJ, Seibel MJ, Baxter RC,
Handelsman DJ, Kazlauskas R & Ho KK. Within-subject variability
and analytic imprecision of insulinlike growth factor axis and
collagen markers: implications for clinical diagnosis and doping tests.
Clinical Chemistry 2008 54 1268–1276. (https://doi.org/10.1373/
clinchem.2008.105726)
44 Clayton P, Chatelain P, Tatò L, Yoo HW, Ambler GR, Belgorosky A,
Quinteiro S, Deal C, Stevens A, Raelson J, et al. A pharmacogenomic
approach to the treatment of children with GH deficiency or Turner
syndrome. European Journal of Endocrinology 2013 169 277–289.
(https://doi.org/10.1530/EJE-13-0069)
45 Coghlan RF, Oberdorf JA, Sienko S, Aiona MD, Boston BA,
Connelly KJ, Bahney C, LaRouche J, Almubarak SM, Coleman DT, et
al. A degradation fragment of type X collagen is a real-time marker
for bone growth velocity. Science Translational Medicine 2017 9
eaan4669. (https://doi.org/10.1126/scitranslmed.aan4669)

Received in final form 20 February 2018
Accepted 26 February 2018
Accepted Preprint published online 26 February 2018

http://www.endocrineconnections.org
https://doi.org/10.1530/EC-18-0047

© 2018 Growth Hormone Research Society
Published by Bioscientifica Ltd

This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License.

Downloaded from Bioscientifica.com at 10/28/2020 11:50:28PM
via St Josephs Hosp & Medical Ctr

